Vor Biopharma (VOR) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.90

Estimate

-$0.72

Surprise

-25.3%

Score today

5.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Vor Biopharma (VOR) reported a wider loss than forecast — adjusted EPS of -$0.90 against the -$0.72 estimate (a 25.3% shortfall).

• Vor Biopharma Reports Third Quarter 2026 Financial Results and Corporate Update — fiscal.ai, 2026-10-30
• Vor Biopharma Files Prospectus For Offering $150M Common Shares — benzinga, 2026-10-30

TrendMatrix currently rates VOR Sell at 5.9/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -25.3% surprise compares with a +8634.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$19.68

Price target

$33.93

Stop

$18.30

Upside to target

+72.4%

Reward-to-risk

5.9:1

Model outputs from TrendMatrix’s engine as of 2026-10-31 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.07B

P/E (fwd)

-5.4

P/E (ttm)

0.1

52-week range

$6.50–$26.76

Off 52-week high

26.5%

RSI (14)

49

Volume vs avg

0.94×

Score today

5.9/10